

Ganirelix Formulation

Vers 5.3	sion	Revision Date: 16.10.2020	SDS Number: 22210-00016		Date of last issue: 13.09.2019 Date of first issue: 15.10.2014		
1. P	1. PRODUCT AND COMPANY IDENTIFICATION						
	Product name		:	Ganirelix Formula	ation		
	Manufa	acturer or supplier's c	detai	ils			
	Compa		:	Organon & Co.			
	Address		:	30 Hudson Street, 33nd floor Jersey City, New Jersey, U.S.A 07302			
	Telephone		:	: 551-430-6000			
	Emergency telephone number		r :	: 215-631-6999			
	E-mail address		:	EHSSTEWARD@organon.com			
		mended use of the cl mended use	hem :	ical and restriction Pharmaceutical	ons on use		
2. H	2. HAZARDS IDENTIFICATION						
Manufacture, Storage and Import of Hazardous Chemicals Rules 1989							
	Classification						
	Not cla	ssified as hazardous a	ccor	ding to criteria laid	down in Part I of Schedule-1.		
	GHS C	lassification					

GHS Classification		
Reproductive toxicity	:	Category 1B
Specific target organ toxicity - repeated exposure	:	Category 1 (Bone marrow, Liver, Adrenal gland, spleen, Ovary)
GHS label elements		
Hazard pictograms	:	
Signal word	:	Danger
Hazard statements	:	H360Fd May damage fertility. Suspected of damaging the un- born child.
		H372 Causes damage to organs (Bone marrow, Liver, Adrenal gland, spleen, Ovary) through prolonged or repeated exposure.
Precautionary statements	:	Prevention:
		P203 Obtain, read and follow all safety instructions before use.P260 Do not breathe mist or vapours.P264 Wash skin thoroughly after handling.P270 Do not eat, drink or smoke when using this product.



Ganirelix Formulation

/ersion 5.3	Revision Date: 16.10.2020	-	S Number: 210-00016	Date of last issue: 13. Date of first issue: 15.			
		P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.					
			Response: P318 IF expos	ed or concerned, get med	lical advice.		
			Storage: P405 Store loc	ked up.			
			Disposal: P501 Dispose of contents/ container to an approved wasted disposal plant.				
	hazards which do no known.	ot res	ult in classifica	tion			
B. COMPO	SITION/INFORMATIC	ON ON	I INGREDIENTS	5			
Subst	ance / Mixture	:	Mixture				
Comp	oonents						
Chem	ical name			CAS-No.	Concentration (% w/w)		
Ganire	elix			124904-93-4	>= 0.01 - < 0.1		
. FIRST A							
Gener	ral advice	:	 In the case of accident or if you feel unwell, seek medical a vice immediately. When symptoms persist or in all cases of doubt seek medic advice. 				
lf inha	lled	:	If inhaled, remo Get medical atte				
In cas	e of skin contact	:	 In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse. 				
In cas	e of eye contact	:	Flush eyes with	water as a precaution.	s and persists.		
lf swa	llowed	:	Get medical attention if irritation develops and persists. If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.				

May damage fertility. Suspected of damaging the unborn Most important symptoms : and effects, both acute and child. Causes damage to organs through prolonged or repeated exposure

ection,
ment
).

5. FIREFIGHTING MEASURES

delayed



Ganirelix Formulation

Version 5.3	Revision Date: 16.10.2020	-	0S Number: 210-00016	Date of last issue: 13.09.2019 Date of first issue: 15.10.2014			
Suitable extinguishing media		:	Water spray Alcohol-resistant f Carbon dioxide (C Dry chemical				
	Unsuitable extinguishing media Specific hazards during fire- fighting Hazardous combustion prod- ucts		None known.				
Speci			Exposure to combustion products may be a hazard to health.				
Hazar			No hazardous cor	nbustion products are known			
Speci ods	fic extinguishing meth-	:	 Use extinguishing measures that are appropriate to lo cumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is s so. Evacuate area. 				
	Special protective equipment for firefighters		In the event of fire, wear self-contained breathing apparatu Use personal protective equipment.				
6. ACCIDENTAL RELEASE MEA			RES				
tive e	Personal precautions, protec- tive equipment and emer- gency procedures		Follow safe handl	ective equipment. ing advice (see section 7) and personal pro- recommendations (see section 8).			
Enviro	onmental precautions	:	Prevent spreading barriers). Retain and dispos	akage or spillage if safe to do so. g over a wide area (e.g. by containment or oil se of contaminated wash water. should be advised if significant spillages			
	ods and materials for nment and cleaning up	:	For large spills, pr ment to keep mat be pumped, store Clean up remainin bent. Local or national n posal of this mate employed in the c mine which regula Sections 13 and 1	absorbent material. Tovide dyking or other appropriate contain- erial from spreading. If dyked material can recovered material in appropriate container. Ing materials from spill with suitable absor- regulations may apply to releases and dis- rial, as well as those materials and items leanup of releases. You will need to deter- ations are applicable. 5 of this SDS provide information regarding tional requirements.			

7. HANDLING AND STORAGE

Technical measures	: See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
Local/Total ventilation	: If sufficient ventilation is unavailable, use with local exhaust ventilation.
Advice on safe handling	: Do not get on skin or clothing.



Basis

Ganirelix Formulation

Versior 5.3	Revision Date: 16.10.2020	SDS Number: 22210-00016	Date of last issue: 13.09.2019 Date of first issue: 15.10.2014
		Do not swallow Avoid contact Wash skin tho Handle in acco practice, base sessment Keep containe Do not eat, dri	
Conditions for safe storage		Store locked u Keep tightly cl	osed.
Ma	aterials to avoid		dance with the particular national regulations. vith the following product types: ng agents

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters Components CAS-No. Value type (Form of exposure) Control parameters / Permissible concentration

		exposure)	concentration				
Ganirelix	124904-93-4	TWA	0.2 µg/m3 (OEB 5)	Internal			
		Wipe limit	2 µg/100 cm ²	Internal			
Engineering measures	to control at vent leakage All engineer design and protect prod	Use closed processing systems or containment technologies to control at source (e.g., glove boxes/isolators) and to pre- vent leakage of compounds into the workplace. All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.					
	Totally enclo are required Operations	equire the use of	nd materials transpor appropriate containn akage of compounds	nent tech-			
Personal protective equipme	ent						
Respiratory protection	: No personal quired.	respiratory prote	ctive equipment norm	nally re-			
Hand protection	•						
Material	: Chemical-re	sistant gloves					
Remarks Eye protection	: Wear safety If the work e mists or aer	nvironment or actorsols, wear the ap	e shields or goggles. tivity involves dusty c opropriate goggles. I face protection if the				



Ganirelix Formulation

Version 5.3	Revision Date: 16.10.2020	SDS Number: 22210-00016	Date of last issue: 13.09.2019 Date of first issue: 15.10.2014				
Skin	and body protection	 potential for direct contact to the face with dusts, mists, or aerosols. Work uniform or laboratory coat. Additional body garments should be used based upon the total should be upon the total should be used based upon the total should be upon total					
		being performed (e.g., sleevelets, apron, gauntlets, disposed skin surfaces. Use appropriate degowning techniques to remove poten contaminated clothing.					
Hygie	ene measures	 If exposure to chemical is likely during typical use, provide ey flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of 					
		engineering co appropriate de industrial hygie	ntrols, proper personal protective equipment, gowning and decontamination procedures, ene monitoring, medical surveillance and the trative controls.				

9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	:	Aqueous solution
Colour	:	No data available
Odour	:	No data available
Odour Threshold	:	No data available
рН	:	5
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	100 °C
Flash point	:	No data available
Evaporation rate	:	No data available
Flammability (solid, gas)	:	Not applicable
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapour pressure	:	23 hPa (20 °C)
Relative vapour density	:	No data available
Relative density	:	1



Ganirelix Formulation

Version 5.3	Revision Date: 16.10.2020	SDS Number 22210-00016	
N Par octa	Solubility(ies) Water solubility Partition coefficient: n- octanol/water Auto-ignition temperature		ely miscible available available
Dec	composition temperature	: No data	available
N	cosity /iscosity, kinematic losive properties	: No data : Not expl	available osive
Oxid	dizing properties ecular weight ticle size	: The sub	stance or mixture is not classified as oxidizing. available available
i ui		. no dulu	

10. STABILITY AND REACTIVITY

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reac-	:	Can react with strong oxidizing agents.
tions		
Conditions to avoid	:	None known.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products		No hazardous decomposition products are known.

11. TOXICOLOGICAL INFORMATION

Information on likely routes of	:	Inhalation
exposure		Skin contact
		Ingestion
		Eye contact

Acute toxicity

Not classified based on available information.

Components:

Ganirelix:

Acute toxicity (other routes of : LD50 (Rat): 40 mg/kg administration)

Skin corrosion/irritation

Not classified based on available information.

Serious eye damage/eye irritation

Not classified based on available information.





rsion	Revision Date: 16.10.2020		Number: 0-00016	Date of last issue: 13.09.2019 Date of first issue: 15.10.2014
<u>Comp</u>	oonents:			
Ganir	elix:			
Speci	es	: R	Rabbit	
Metho	bd	: C	Draize Test	
Resul	t	: N	Aild eye irritation	
Resp	iratory or skin sens	itisation		
Skin s	sensitisation			
Not cl	assified based on av	ailable inf	formation.	
Respi	iratory sensitisatior	า		
Not cl	assified based on av	ailable inf	formation.	
<u>Comp</u>	oonents:			
Ganir	elix:			
Test 7	Гуре	: N	Aaximisation Tes	t
Speci	es	· (Guinea pig	
Resul			negative	
Resul				
Resul Germ	t	: n	negative	
Resul Germ Not cl	t cell mutagenicity	: n	negative	
Resul Germ Not cl	t cell mutagenicity assified based on av ponents:	: n	negative	
Resul Germ Not cl <u>Comp</u> Ganir	t cell mutagenicity assified based on av ponents: relix:	: n ailable inf	formation.	e mutation assay
Resul Germ Not cl <u>Comp</u> Ganir	t cell mutagenicity assified based on av ponents:	: n ailable inf : T	formation.	e mutation assay nonella typhimurium
Resul Germ Not cl <u>Comp</u> Ganir	t cell mutagenicity assified based on av ponents: relix:	: n ailable inf : T T	formation.	
Resul Germ Not cl <u>Comp</u> Ganir	t cell mutagenicity assified based on av ponents: relix:	: n ailable inf : T T R	formation. formation. fest Type: revers fest system: Salr Result: negative	nonella typhimurium
Resul Germ Not cl <u>Comp</u> Ganir	t cell mutagenicity assified based on av ponents: relix:	: n ailable inf : T T R T	formation. formation. fest Type: revers fest system: Salr Result: negative	nonella typhimurium e mutation assay
Resul Germ Not cl <u>Comp</u> Ganir	t cell mutagenicity assified based on av ponents: relix:	: n ailable inf : T R T T T T	formation. formation. fest Type: revers fest system: Salr Result: negative fest Type: revers	nonella typhimurium e mutation assay
Resul Germ Not cl <u>Comp</u> Ganir	t cell mutagenicity assified based on av ponents: relix:	: n ailable inf : T R T R	formation. Test Type: reverse Test system: Salre Result: negative Test Type: reverse Test system: Esc Result: negative	nonella typhimurium e mutation assay herichia coli
Resul Germ Not cl <u>Comp</u> Ganir	t cell mutagenicity assified based on av ponents: relix:	: n ailable inf : T R T R T T R	formation. formation. fest Type: revers est system: Salr Result: negative fest Type: revers fest system: Esc Result: negative fest Type: in vitro	nonella typhimurium e mutation assay herichia coli
Resul Germ Not cl <u>Comp</u> Ganir	t cell mutagenicity assified based on av ponents: relix:	: n ailable inf : T R T R T T R T T T	formation. formation. fest Type: revers est system: Salr Result: negative fest Type: revers fest system: Esc Result: negative fest Type: in vitro	nonella typhimurium e mutation assay herichia coli o assay
Resul Germ Not cl Comp Ganir Genot	t cell mutagenicity assified based on av ponents: relix:	: n ailable inf : T R T R T R T R	formation. Fest Type: revers Test system: Salr Result: negative Test Type: revers Test system: Esc Result: negative Test Type: in vitro Test system: Chir Result: negative	nonella typhimurium e mutation assay herichia coli o assay hese hamster ovary cells
Resul Germ Not cl Comp Ganir Genot	t cell mutagenicity assified based on av <u>ponents:</u> relix: toxicity in vitro	: n ailable inf : T T R T R T R T S	formation. formation. fest Type: revers fest system: Salr Result: negative fest Type: revers fest system: Esc Result: negative fest Type: in vitro fest system: Chir Result: negative fest Type: In vivo Species: Mouse	nonella typhimurium e mutation assay herichia coli o assay hese hamster ovary cells
Resul Germ Not cl Comp Ganir Genot	t cell mutagenicity assified based on av <u>ponents:</u> relix: toxicity in vitro	: n ailable inf : T R T R T R T R S A	formation. formation. fest Type: revers fest system: Salr Result: negative fest Type: revers fest system: Esc Result: negative fest Type: in vitro fest system: Chir Result: negative fest Type: In vivo Species: Mouse Application Route	nonella typhimurium e mutation assay herichia coli o assay hese hamster ovary cells
Resul Germ Not cl Comp Ganir Genot	t cell mutagenicity assified based on av <u>ponents:</u> relix: toxicity in vitro	: n ailable inf : T R T R T R T R S A	formation. formation. fest Type: revers fest system: Salr Result: negative fest Type: revers fest system: Esc Result: negative fest Type: in vitro fest system: Chir Result: negative fest Type: In vivo Species: Mouse	nonella typhimurium e mutation assay herichia coli o assay hese hamster ovary cells
Resul Germ Not cl Comp Ganir Genot	t cell mutagenicity assified based on av <u>ponents:</u> relix: toxicity in vitro	: n ailable inf : T R T R T R T R R R R R R R R R	formation. Fest Type: reverse Fest system: Salre Result: negative Fest Type: reverse Fest Type: reverse Fest Type: in vitro Fest	nonella typhimurium e mutation assay herichia coli o assay hese hamster ovary cells

Carcinogenicity

Not classified based on available information.

Reproductive toxicity

May damage fertility. Suspected of damaging the unborn child.

Ganirelix Formulation



Version 5.3	Revision Date: 16.10.2020		DS Number: 210-00016	Date of last issue: 13.09.2019 Date of first issue: 15.10.2014
<u>Co</u>	<u>mponents:</u>			
	nirelix: acts on fertility	 Test Type: Fertility/early embryonic Species: Rat Application Route: Subcutaneous Duration of Single Treatment: 13 W Fertility: LOAEL: 0.1 µg/kg Result: Effects on fertility Test Type: Fertility/early embryonic 		: Subcutaneous Treatment: 13 Weeks).1 μg/kg fertility y/early embryonic development
			Fertility: LOAEL: 1	: Subcutaneous Treatment: 8 Weeks ΙΟ μg/kg on mating performance, Effects on fertility
			Species: Monkey Application Route	: Subcutaneous 0.02 mg/kg body weight
Effe mei	ects on foetal develop- nt	:	Species: Rat, fem Application Route	: Subcutaneous icity: LOAEL: 10 μg/kg
			Species: Rabbit, f Application Route	: Subcutaneous icity: LOAEL: 30 μg/kg
	productive toxicity - As- sment	:	ity, based on anim	adverse effects on sexual function and fertil- nal experiments., Some evidence of adverse oment, based on animal experiments.

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

Causes damage to organs (Bone marrow, Liver, Adrenal gland, spleen, Ovary) through prolonged or repeated exposure.

Components:

Ganirelix:

Exposure routes Target Organs Assessment	:	Ingestion Bone marrow, Liver, Adrenal gland, spleen, Ovary Causes damage to organs through prolonged or repeated
		exposure.





/ersion 5.3	Revision Date: 16.10.2020	SDS Number: 22210-00016	Date of last issue: 13.09.2019 Date of first issue: 15.10.2014
Repe	ated dose toxicity		
Com	ponents:		
Gani	relix:		
Expo	EL	: Rat : 0.02 mg/kg : 2 mg/kg : Subcutaneous : 6 Months : Bone marrow	
Expo		: Mouse, female : 0.3 mg/kg : Subcutaneous : 3 Months : Liver, Adrenal g	gland, spleen, Ovary
Expo		: Mouse, male : 3 mg/kg : Subcutaneous : 3 Months : Liver, Adrenal g	gland, spleen
	EL cation Route sure time	: Monkey : 2.5 mg/kg : Subcutaneous : 6 Months : No significant a	adverse effects were reported
•	ration toxicity lassified based on ava	ilable information.	
Expe	rience with human e	xposure	
•			

Components:

Ganirelix:

Inhalation

Symptoms: The most common side effects are:, vaginal bleeding, Headache, Abdominal pain, Nausea, ectopic pregnancy, miscarriage

12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Ganirelix:

Ecotoxicology Assessment

Acute aquatic toxicity	:	No data available
------------------------	---	-------------------

:

Chronic aquatic toxicity	:	No data available
--------------------------	---	-------------------

Ganirelix Formulation



Version 5.3	Revision Date: 16.10.2020	SDS Number: 22210-00016	Date of last issue: 13.09.2019 Date of first issue: 15.10.2014
	i stence and degrada ata available	bility	
	ccumulative potentia ata available	l	
	lity in soil ata available		
	r adverse effects ata available		
13. DISPC	SAL CONSIDERATI	ONS	
Wast	osal methods e from residues aminated packaging	: Empty contain dling site for re	accordance with local regulations. ers should be taken to an approved waste han- ecycling or disposal. e specified: Dispose of as unused product.
14. TRAN	SPORT INFORMATIO	DN	
Interi	national Regulations		
UNR ⁻ Not re	TDG egulated as a dangerc	ous good	
	-DGR egulated as a dangerd	ous good	
	-Code egulated as a dangero	ous good	
	sport in bulk accordi pplicable for product a	ng to IMO instrumen as supplied.	ts
15. REGU	LATORY INFORMAT	ION	
Safet ture	y, health and enviro	nmental regulations/	legislation specific for the substance or mix
The c AICS	• •	roduct are reported : not determined	in the following inventories:
DSL		: not determined	t de la constante de

16. OTHER INFORMATION

Further information

Sources of key data used to	:	Internal technical data, data from raw material SDSs, OECD
compile the Safety Data		eChem Portal search results and European Chemicals Agen-





Version 5.3	Revision Date: 16.10.2020	SDS Number: 22210-00016	Date of last issue: 13.09.2019 Date of first issue: 15.10.2014
Sheet		cy, http://ech	a.europa.eu/
Date format		: dd.mm.yyyy	

Full text of other abbreviations

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR -Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response: ELx - Loading rate associated with x% response: EmS - Emergency Schedule: ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose): MARPOL - International Convention for the Prevention of Pollution from Ships: n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration: NO(A)EL - No Observed (Adverse) Effect Level: NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IN / EN